Rituximab-related viral infections in lymphoma patients

被引:261
作者
Aksoy, Sercan [1 ]
Harputluoglu, Hakan [1 ]
Kilickap, Saadettin [1 ]
Dede, Didem Sener [1 ]
Dizdar, Omer [1 ]
Altundag, Kadri [1 ]
Barista, Ibrahim [1 ]
机构
[1] Hacettepe Univ, Dept Med Oncol, Ankara, Turkey
关键词
rituximab; non-Hodgkin's lymphoma; viral infections;
D O I
10.1080/10428190701411441
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, a human/mouse chimeric monoclonal antibody, rituximab, has been successfully used to treat cases of B-cell non-Hodgkin's lymphoma and some autoimmune diseases. However, several viral infections related to rituximab have been reported in the literature, but were not well characterized. To further investigate this topic, relevant English language studies were identified through Medline. There were 64 previously reported cases of serious viral infection after rituximab treatment. The median age of the cases was 61 years (range: 21 - 79). The median time period from the start of rituximab treatment to viral infection diagnosis was 5.0 months (range: 1 - 20). The most frequently experienced viral infections were hepatitis B virus (HBV) (39.1%, n = 25), cytomegalovirus infection (CMV) (23.4%, n = 15), varicella-zoster virus (VZV) ( 9.4%, n = 6), and others (28.1%, n = 18). Of the patients with HBV infections, 13 (52.0%) died due to hepatic failure. Among the 39 cases that had viral infections other than HBV, 13 died due to these specific infections. In this study, about 50% of the rituximab-related HBV infections resulted in death, whereas this was the case in only 33% of the cases with other infections. Close monitoring for viral infection, particularly HBV and CMV, in patients treated with rituximab should be recommended.
引用
收藏
页码:1307 / 1312
页数:6
相关论文
共 61 条
[1]   Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient [J].
Aksoy, S ;
Abali, H ;
Kilickap, S ;
Erman, M ;
Kars, A .
CLINICAL AND LABORATORY HAEMATOLOGY, 2006, 28 (03) :211-214
[2]   Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000 [J].
Archimbaud, C ;
Bailly, JL ;
Chambon, M ;
Tournilhac, O ;
Travade, P ;
Peigue-Lafeuille, H .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (10) :4605-4610
[3]  
Bermúdez A, 2000, HAEMATOLOGICA, V85, P894
[4]   Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].
Byrd, JC ;
Peterson, BL ;
Morrison, VA ;
Park, K ;
Jacobson, R ;
Hoke, E ;
Vardiman, JW ;
Rai, K ;
Schiffer, CA ;
Larson, RA .
BLOOD, 2003, 101 (01) :6-14
[5]  
*CDCP, 2000, BIOL BLOOD MARROW TR, V6, P715
[6]  
*CDCP, 2000, BIOL BLOOD MARROW TR, V6, P717
[7]   INFECTIOUS AND IMMUNOSUPPRESSIVE COMPLICATIONS OF PURINE ANALOG THERAPY [J].
CHESON, BD .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) :2431-2448
[8]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[9]   Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: Role of lamivudine prophylaxis [J].
Coiffier, Bertrand .
CANCER INVESTIGATION, 2006, 24 (05) :548-552
[10]  
CORNELY OA, 2005, J CLIN ONCOL, V23, P2562